Valneva (NASDAQ:VALN) Earns Buy Rating from HC Wainwright

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $17.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 137.10% from the stock’s current price.

Valneva Trading Down 1.1 %

Shares of VALN stock opened at $7.17 on Friday. Valneva has a 1 year low of $3.62 and a 1 year high of $9.50. The firm’s fifty day simple moving average is $6.34 and its 200 day simple moving average is $5.59. The firm has a market capitalization of $582.64 million, a P/E ratio of -55.15 and a beta of 1.93. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Valneva (NASDAQ:VALN) last announced its earnings results on Wednesday, March 19th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. As a group, sell-side analysts predict that Valneva will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new position in shares of Valneva SE (NASDAQ:VALN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.